Navigate Placebo Response: Insights and Mitigation Strategies for Clinical Excellence

In this webinar, attendees will delve into the forefront of placebo response research and mitigation tactics within contemporary clinical trials. The panel of experts from academia, industry and service sectors will dissect the placebo response phenomenon and offer insights right from the latest biological research to pragmatic methodologies for trial success.

Attendees will gain a comprehensive understanding that empowers drug developers to navigate this complex terrain effectively, enhancing the precision of treatment effect estimations and averting trial failures.

Benefit from these insights and explore integrated approaches that can pave the way for success in the ever-evolving landscape of modern clinical development.

Register for this webinar today to discover the key ideas to mastering placebo responses in 2024 and beyond.

Speakers

Luana Colloca, PhD, MPower Distinguished Professor, University of Maryland School of Nursing Baltimore

Dr. Luana Colloca is renowned for her pioneering work in pain and translational symptom science. Graduating from the Magna Graecia University of Catanzaro School of Medicine, Italy, she earned her MD before completing her PhD in Neuroscience and a Master’s degree in Bioethics at the University of Turin. Her post-doctoral training in brain imaging at the Karolinska Institute, Stockholm, Sweden, further enriched her expertise. Dr. Colloca’s research on placebo and nocebo effects has significantly advanced our understanding of pain modulation in humans. Utilizing a multifaceted approach, she integrates psychopharmacological, neurobiological and behavioral aspects and has made significant contributions to top-ranked journals and delivered over 300 lectures worldwide. Her outstanding achievements have earned her prestigious awards, including the Dubner Award and Patrick Wall International Award from the International Association for the Study of Pain (IASP), solidifying her international reputation as a leading figure in her field.

Message Presenter

Daniele Laverdure-Dupont, PhD, COA Specialist for Patient-Centered Outcomes, Clinical Development, H. Lundbeck A/S

Dr. Daniele Laverdure-Dupont is at the forefront of patient-centric drug development as a COA Specialist for Patient-Centered Outcomes in Global Clinical Development at H. Lundbeck A/S. With over a decade of experience at Lundbeck, she specializes in optimizing clinical trial designs to capture patients’ experiences while adhering to regulatory standards. Danièle has pioneered novel quantitative analysis methods to address placebo effects in CNS trials, ensuring robust trial designs and meaningful endpoints that align with Lundbeck’s mission of improving patients’ lives. A thought leader in advocating for patient-reported outcomes as essential endpoints in CNS trials, Danièle’s work has a global impact, resonating across cultures and healthcare systems.

Message Presenter

Peter Schüler, MD, Senior Vice President, Drug Development Neurosciences, ICON plc

Peter Schüler began his post-academic career at Siemens Medical Imaging, followed by Pharmacia as Head of Medical Affairs, CNS Germany. He moved to the CRO business in 2000 as Vice President of Global Medical Affairs at PRA before joining ICON, where he currently serves as Senior Vice President of Drug Development Solutions CNS. With board certifications in neurology and pharmaceutical medicine, he blends scientific acumen with methodological leadership to optimize study designs and drive innovation in clinical research.

Message Presenter

Thor Ostenfeld, PhD, Head of Clinical Development, Grunenthal

Thor Ostenfeld is a distinguished leader in scientific research and pharmaceutical development, boasting a strong academic background. He studied pharmacology and medicine at Dundee University, followed by a PhD from Cambridge University and an MBA from Imperial College. Thor Ostenfeld commenced his industry journey at GSK, where he held progressive leadership positions while concurrently consulting as an anesthesiologist at Cambridge University Hospitals. His expertise, particularly in neuroscience, was further demonstrated as he rose to the role of Head of Clinical Development Neuroscience at AstraZeneca and he has recently assumed the role of Head of Clinical Development at Grünenthal.

Message Presenter

Dominique Demolle, PhD, CEO, Cognivia

Dr. Dominique Demolle is the Chief Executive Officer at Cognivia. Dominique holds a PhD in biochemistry from the University of Brussels. She has held various leadership positions at Eli Lilly and Company and has extensive knowledge in global early phase drug development. Dominique consulted with pharmas and biotechs before founding Cognivia. Dominique has contributed to the clinical development of dozens of drugs and several launches. Most recently, she has been recognized as one of the 2022’s Most Inspiring People in the life sciences for the annual PharmaVoice 100 awards.

Message Presenter